Arcturus Therapeutics Holdings Dirección
Dirección controles de criterios 2/4
Arcturus Therapeutics Holdings' El consejero delegado es Joe Payne , nombrado en Mar 2013, tiene un mandato de 11.08 años. la remuneración anual total es $5.59M , compuesta por 11.3% salario y 88.7% primas, incluidas acciones y opciones de la empresa. posee directamente 5.5% de las acciones de la empresa, por valor de $49.98M . La antigüedad media del equipo directivo y del consejo de administración es de 3.7 años y 5.3 años respectivamente.
Información clave
Joe Payne
Chief Executive Officer (CEO)
US$5.6m
Compensación total
| Porcentaje del salario del CEO | 11.3% |
| Permanencia del CEO | 11.1yrs |
| Participación del CEO | 5.5% |
| Permanencia media de la dirección | 3.7yrs |
| Promedio de permanencia en la Junta Directiva | 5.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business
Apr 09
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking
Feb 06Arcturus: H1 2024 Rare Disease Drug Data On Deck
Jan 31Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?
Jan 11Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?
Dec 14Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business
Sep 14Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates
Aug 08Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Jul 19Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher
May 18Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet
May 02Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money
Dec 28Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 23Arcturus rises 6% on $63.2M award from U.S. government for mRNA vaccine
Aug 31Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)
Aug 15Arcturus Therapeutics downgraded to underperform at Raymond James on program setbacks
Aug 10Arcturus: Potential Based On Rare Disease Therapy ARCT-810
Jun 07These Analysts Think Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Sales Are Under Threat
May 11Arcturus: Biotech With Great Potential In Covid-19 Vaccine Space
Apr 25Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) Weighed On By Its Debt Load?
Jan 22Arcturus: Emerging Covid Variants May Provide A Raison D'êTre
Nov 28Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$30m |
| Sep 30 2023 | n/a | n/a | US$99m |
| Jun 30 2023 | n/a | n/a | US$80m |
| Mar 31 2023 | n/a | n/a | US$111m |
| Dec 31 2022 | US$6m | US$630k | US$9m |
| Sep 30 2022 | n/a | n/a | -US$147m |
| Jun 30 2022 | n/a | n/a | -US$165m |
| Mar 31 2022 | n/a | n/a | -US$198m |
| Dec 31 2021 | US$960k | US$600k | -US$204m |
| Sep 30 2021 | n/a | n/a | -US$196m |
| Jun 30 2021 | n/a | n/a | -US$163m |
| Mar 31 2021 | n/a | n/a | -US$119m |
| Dec 31 2020 | US$13m | US$500k | -US$72m |
| Sep 30 2020 | n/a | n/a | -US$52m |
| Jun 30 2020 | n/a | n/a | -US$38m |
| Mar 31 2020 | n/a | n/a | -US$29m |
| Dec 31 2019 | US$1m | US$450k | -US$26m |
| Sep 30 2019 | n/a | n/a | -US$16m |
| Jun 30 2019 | n/a | n/a | -US$13m |
| Mar 31 2019 | n/a | n/a | -US$22m |
| Dec 31 2018 | US$3m | US$425k | -US$22m |
| Sep 30 2018 | n/a | n/a | -US$26m |
| Jun 30 2018 | n/a | n/a | -US$25m |
| Mar 31 2018 | n/a | n/a | -US$16m |
| Dec 31 2017 | US$449k | US$384k | -US$11m |
Compensación vs. Mercado: Joe($USD5.59M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.42M).
Compensación vs. Ingresos: La compensación de Joe ha aumentado mientras la empresa no es rentable.
CEO
Joe Payne (51 yo)
11.1yrs
Permanencia
US$5,594,000
Compensación
Mr. Joseph E. Payne, also known as Joe, M.Sc. has been Independent Non-Executive Director of Vallon Pharmaceuticals, Inc. since June 22, 2018. Mr. Payne has been Director of Arcturus since November 2017. H...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 11.1yrs | US$5.59m | 5.5% $ 44.6m | |
| Founder | 11.3yrs | US$3.11m | 1.76% $ 14.3m | |
| CFO & Director | 5.7yrs | US$3.15m | 1.01% $ 8.2m | |
| Vice President and Head of IR/PR & Marketing | no data | sin datos | sin datos | |
| Chief Legal Officer | 3.7yrs | US$560.00k | sin datos | |
| Chief Human Resources Officer | less than a year | sin datos | sin datos | |
| Chief Business Officer | 5.6yrs | sin datos | sin datos | |
| Chief Medical Officer | less than a year | sin datos | sin datos | |
| Chief Development Officer | less than a year | sin datos | sin datos | |
| Controller | less than a year | sin datos | sin datos |
3.7yrs
Permanencia media
55yo
Promedio de edad
Equipo directivo experimentado: ARCTEl equipo directivo de la empresa se considera experimentado (3.6 años de antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 11.1yrs | US$5.59m | 5.5% $ 44.6m | |
| CFO & Director | 4.6yrs | US$3.15m | 1.01% $ 8.2m | |
| Independent Chairman of the Board | 5.9yrs | US$305.30k | 0.36% $ 2.9m | |
| Independent Director | 4.6yrs | US$293.35k | 0% $ 0 | |
| Independent Director | 5.9yrs | US$302.80k | 0.037% $ 301.3k | |
| Independent Director | 5.9yrs | US$292.80k | 0.093% $ 751.5k | |
| Member of the Vaccine Platform Scientific Advisory Board | 3.8yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 9.3yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 8.4yrs | sin datos | sin datos | |
| Member of the Vaccine Platform Scientific Advisory Board | 3.8yrs | sin datos | sin datos | |
| Strategic Clinical Advisor & Member of Scientific Advisory Board | 2.1yrs | US$644.00k | sin datos | |
| Member of the Vaccine Platform Scientific Advisory Board | 3.8yrs | sin datos | sin datos |
5.3yrs
Permanencia media
64yo
Promedio de edad
Junta con experiencia: La junta directiva de ARCT se considera experimentada (4.9 años de antigüedad promedio).